Study on Pacritinib for Metastatic Castrate-Resistant Prostate Cancer After Androgen Receptor Treatment

Inclusion Criteria

• Men aged 18 years or older.
• Confirmed diagnosis of prostate adenocarcinoma.
• Evidence of cancer spread to other parts of the body, confirmed by scans.
• Cancer that has progressed during or after hormone therapy and treatment with at least one androgen receptor signaling inhibitor.
• Low testosterone levels (less than 50 ng/dL).
• Good overall health with a performance status score of 0-1.
• No previous treatment with JAK2 inhibitors.
• Heart function with an ejection fraction of 50% or higher.
• Adequate organ function based on specific blood tests.
• Willingness to use effective birth control methods during the study and for 30 days after the last dose.
• Ability to understand and sign a consent form.
• Provide a tumor sample from a recent biopsy showing high STAT5 activation levels.

Exclusion Criteria

• No positive STAT5 activation in cancer cell biopsies.
• Previous treatment with pacritinib.
• Use of experimental drugs within 28 days before starting the study.
• Use of certain medications within seven days before starting the study.
• Uncontrolled high blood pressure.
• Severe liver problems.
• Uncontrolled illnesses or conditions that could interfere with the study.
• Recent significant bleeding issues.
• Use of medications that increase bleeding risk or affect heart rhythm within 14 days before starting the study.
• History of serious heart conditions within six months before starting the study.
• Heart rhythm issues or heart failure.
• Conditions affecting the absorption of oral medication.
• Other cancers within three years, except for certain skin cancers.
• Active infections like HIV or hepatitis.